-
公开(公告)号：US09688616B2
公开(公告)日：2017-06-27
申请号：US15219478
申请日：2016-07-26
Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
Inventor： Erik Fenster , Melissa Fleury , Adam D. Hughes
IPC: A61K31/40 , A61K31/42 , A61K31/44 , A61K31/197 , A61K31/397 , A61K31/5375 , C07D205/04 , C07D207/09 , C07D207/14 , C07D213/56 , C07C235/34 , C07D261/04 , C07D295/32 , C07C243/38 , C07D491/107 , C07D213/75 , C07C259/04 , C07D309/08 , C07D233/06 , C07D401/04 , C07D405/06 , C07D239/36 , C07D261/02 , C07C233/56 , C07C235/12 , C07C235/20 , C07C235/74 , C07C235/78 , C07D265/30 , C07D207/08 , C07D207/12 , C07D207/16 , C07D493/10 , C07C243/24 , C07C243/32 , C07D211/22 , C07D211/38 , C07D211/42 , C07D211/46 , C07D211/48 , C07D211/60 , C07D211/62 , C07D213/61 , C07D307/68 , A61K31/4015 , A61K31/495 , A61K45/06 , A61K31/192 , A61K31/4406 , C07C235/80 , C07D213/65 , A61K31/341 , A61K31/4409 , C07D213/86 , C07D213/87
CPC classification number: C07C243/38 , A61K31/192 , A61K31/197 , A61K31/341 , A61K31/397 , A61K31/40 , A61K31/4015 , A61K31/42 , A61K31/44 , A61K31/4406 , A61K31/4409 , A61K31/495 , A61K31/5375 , A61K45/06 , C07C233/56 , C07C235/12 , C07C235/20 , C07C235/34 , C07C235/74 , C07C235/78 , C07C235/80 , C07C243/24 , C07C243/32 , C07C259/04 , C07C2601/08 , C07C2601/16 , C07D205/04 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/22 , C07D211/38 , C07D211/42 , C07D211/46 , C07D211/48 , C07D211/60 , C07D211/62 , C07D213/56 , C07D213/61 , C07D213/65 , C07D213/75 , C07D213/86 , C07D213/87 , C07D233/06 , C07D239/36 , C07D261/02 , C07D261/04 , C07D265/30 , C07D295/32 , C07D307/68 , C07D309/08 , C07D401/04 , C07D405/06 , C07D491/107 , C07D493/10
Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
-
2.发明申请Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase 审中-公开使用组蛋白脱乙酰酶抑制剂治疗认知障碍的方法公开(公告)号：US20170000749A1
公开(公告)日：2017-01-05
申请号：US15016126
申请日：2016-02-04
Applicant: Forum Pharmaceuticals, Inc.
Inventor： Kathryn Rogers , Holger Patzke
IPC: A61K31/185 , A61K31/5513 , A61K31/554 , A61K31/551 , A61K31/7052 , A61K31/506 , A61K31/407 , A61K31/427 , A61K31/497 , A61K31/55 , A61K31/505 , A61K31/335 , A61K31/404 , A61K31/5415 , A61K31/437 , A61K31/538 , A61K31/429 , A61K31/553
CPC classification number: A61K31/185 , A61K31/335 , A61K31/404 , A61K31/407 , A61K31/427 , A61K31/429 , A61K31/437 , A61K31/497 , A61K31/505 , A61K31/506 , A61K31/538 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/553 , A61K31/554 , A61K31/7052 , C07C243/32 , C07C2603/32 , C07D243/38 , C07D267/20 , C07D281/16 , C07D471/04 , C07D487/04 , C07D487/08 , C07D487/16 , C07D498/04 , C07H17/00
Abstract: This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.
Abstract translation: Q，J，L和Z如说明书中所定义。
-
公开(公告)号：US09040709B2
公开(公告)日：2015-05-26
申请号：US14483508
申请日：2014-09-11
Applicant: Sumitomo Chemical Company, Limited
Inventor： Markus Jachmann , Takayuki Wakamatsu , Mitsuharu Anryu
IPC: C07C323/48 , C07C59/84 , C07C59/88 , C07C69/738 , C07C243/32 , C07C251/76 , C07C315/04 , C07C317/28 , C07C319/20 , C07D237/18 , C07D209/24 , C07D237/16 , C07D403/04 , C07D209/18
CPC classification number: C07C323/48 , C07C59/84 , C07C59/88 , C07C69/738 , C07C243/32 , C07C251/76 , C07C315/04 , C07C317/28 , C07C319/20 , C07D209/18 , C07D209/24 , C07D213/56 , C07D237/16 , C07D237/18 , C07D403/04
Abstract: The present invention relates to a novel method for producing a pyridazinone compound and an intermediate thereof as shown in the following scheme: wherein the symbols are as defined in the specification.
Abstract translation: 本发明涉及如下方案所示的哒嗪酮化合物及其中间体的制备方法：其中符号如说明书中所定义。
-
公开(公告)号：US20150011597A1
公开(公告)日：2015-01-08
申请号：US14227536
申请日：2014-03-27
Applicant: Sharath Hegde , Daniel Marquess
Inventor： Sharath Hegde , Daniel Marquess
IPC: C07C237/20 , C07C323/22 , C07C243/32 , C07D257/04
CPC classification number: C07C237/20 , C07C243/32 , C07C319/12 , C07C323/22 , C07C323/41 , C07C323/60 , C07C2601/14 , C07D257/04
Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
Abstract translation: 本发明涉及式I化合物：其中Ar，r，R 3，X和R 5-7如说明书中所定义，及其药学上可接受的盐。 式I的化合物具有AT1受体拮抗剂活性和去皮质激素抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
5.发明申请公开(公告)号：US20140378688A1
公开(公告)日：2014-12-25
申请号：US14483508
申请日：2014-09-11
Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
Inventor： Markus JACHMANN , Takayuki WAKAMATSU , Mitsuharu ANRYU
IPC: C07C323/48 , C07D209/18
CPC classification number: C07C323/48 , C07C59/84 , C07C59/88 , C07C69/738 , C07C243/32 , C07C251/76 , C07C315/04 , C07C317/28 , C07C319/20 , C07D209/18 , C07D209/24 , C07D213/56 , C07D237/16 , C07D237/18 , C07D403/04
Abstract: The present invention relates to a novel method for producing a pyridazinone compound and an intermediate thereof as shown in the following scheme: wherein the symbols are as defined in the specification.
Abstract translation: 本发明涉及如下方案所示的哒嗪酮化合物及其中间体的制备方法：其中符号如说明书中所定义。
-
Patent Agency Ranking
公开(公告)号：US08901169B2
公开(公告)日：2014-12-02
申请号：US14196624
申请日：2014-03-04
Applicant: Erik Fenster , Melissa Fleury , Adam D. Hughes
Inventor： Erik Fenster , Melissa Fleury , Adam D. Hughes
IPC: C07C235/74 , A61K31/7048 , C07C231/02 , A61K31/24 , C07D407/12 , A61K31/365 , A61K31/22 , C07D317/40 , A61K31/265 , C07C243/28 , C07C241/02 , A61P9/12 , A61P9/04 , A61P13/12 , A61K31/197 , A61K31/44 , C07D205/04 , A61K31/5375 , A61K31/397 , C07D207/09 , C07D491/107 , C07C235/34 , C07D261/04 , C07D295/32 , A61K31/40 , C07D213/56 , A61K31/42 , C07D207/14
CPC classification number: C07C243/38 , A61K31/192 , A61K31/197 , A61K31/341 , A61K31/397 , A61K31/40 , A61K31/4015 , A61K31/42 , A61K31/44 , A61K31/4406 , A61K31/4409 , A61K31/495 , A61K31/5375 , A61K45/06 , C07C233/56 , C07C235/12 , C07C235/20 , C07C235/34 , C07C235/74 , C07C235/78 , C07C235/80 , C07C243/24 , C07C243/32 , C07C259/04 , C07C2601/08 , C07C2601/16 , C07D205/04 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/22 , C07D211/38 , C07D211/42 , C07D211/46 , C07D211/48 , C07D211/60 , C07D211/62 , C07D213/56 , C07D213/61 , C07D213/65 , C07D213/75 , C07D213/86 , C07D213/87 , C07D233/06 , C07D239/36 , C07D261/02 , C07D261/04 , C07D265/30 , C07D295/32 , C07D307/68 , C07D309/08 , C07D401/04 , C07D405/06 , C07D491/107 , C07D493/10
Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
Abstract translation: 一方面，本发明涉及具有下式的化合物：其中R1-R5和X如说明书中所定义，或其药学上可接受的盐。 这些化合物具有去血清抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20120322769A1
公开(公告)日：2012-12-20
申请号：US13579373
申请日：2011-02-16
Applicant: Ching-Hong Yang , Xin Chen , Eric J. Toone
Inventor： Ching-Hong Yang , Xin Chen , Eric J. Toone
IPC: C12N1/36 , A61P31/04 , A01P1/00 , A01N37/10 , C07C57/30 , C07C57/38 , C07D333/24 , A61K31/381 , A01N43/10 , C07D209/18 , A61K31/405 , A01N43/38 , C07D213/55 , A61K31/435 , A01N43/40 , C07D233/64 , A61K31/4172 , A01N43/50 , C07C59/13 , C07C235/42 , A61K31/165 , A01N37/18 , C07F9/40 , A61K31/662 , A01N57/22 , A61K31/192
CPC classification number: C07C259/06 , A61K31/05 , A61K31/137 , A61K31/165 , A61K31/185 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/216 , A61K31/255 , A61K31/277 , A61K31/341 , A61K31/343 , A61K31/381 , A61K31/4035 , A61K31/404 , A61K31/4172 , A61K31/4178 , A61K31/4406 , A61K31/4409 , A61K31/4439 , A61K31/662 , A61K31/683 , C07C211/29 , C07C215/54 , C07C233/65 , C07C235/34 , C07C237/20 , C07C243/32 , C07C259/08 , C07C309/24 , C07C309/68 , C07C2601/02 , C07D209/14 , C07D209/48 , C07D209/86 , C07D213/56 , C07D233/64 , C07D307/52 , C07D307/79 , C07D333/24 , C07D333/60 , C07D403/06 , C07D405/06 , C07F9/3826 , Y02A50/475 , Y02A50/481
Abstract: A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein.
Abstract translation: 一种减少包含GacS / GacA型系统，HrpX / HrpY型系统，T3SS型系统和Rsm型系统中的至少一种的细菌中的毒力的方法，所述方法包括使细菌与 有效量的本文所述的化合物。
-
公开(公告)号：US20120129900A1
公开(公告)日：2012-05-24
申请号：US13361099
申请日：2012-01-30
Applicant: Seok-Ki CHOI , Paul R. FATHEREE , Sharath HEGDE , Ryan HUDSON , Keith JENDZA , Daniel MARQUESS , Robert M. MCKINNELL , Vivek SASIKUMAR
Inventor： Seok-Ki CHOI , Paul R. FATHEREE , Sharath HEGDE , Ryan HUDSON , Keith JENDZA , Daniel MARQUESS , Robert M. MCKINNELL , Vivek SASIKUMAR
IPC: A61K31/41 , A61P9/12 , A61P9/04 , A61K31/195 , A61K31/18
CPC classification number: C07C237/20 , C07C243/32 , C07C319/12 , C07C323/22 , C07C323/41 , C07C323/60 , C07C2601/14 , C07D257/04
Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
Abstract translation: 本发明涉及式I化合物：其中Ar，r，R 3，X和R 5-7如说明书中所定义，及其药学上可接受的盐。 式I的化合物具有AT1受体拮抗剂活性和去皮质激素抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US08143298B2
公开(公告)日：2012-03-27
申请号：US12826976
申请日：2010-06-30
Applicant: Seok-Ki Choi , Paul R. Fatheree , Ryan Hudson , Keith Jendza , Robert Murray McKinnell , Vivek Sasikumar
Inventor： Seok-Ki Choi , Paul R. Fatheree , Ryan Hudson , Keith Jendza , Robert Murray McKinnell , Vivek Sasikumar
CPC classification number: C07C237/20 , C07C243/32 , C07C319/12 , C07C323/22 , C07C323/41 , C07C323/60 , C07C2601/14 , C07D257/04
Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
Abstract translation: 本发明涉及式I化合物：其中Ar，r，R 3，X和R 5-7如说明书中所定义，及其药学上可接受的盐。 式I的化合物具有AT1受体拮抗剂活性和去皮质激素抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US07019003B2
公开(公告)日：2006-03-28
申请号：US10469433
申请日：2002-03-01
Applicant: Jia-Ning Xiang , Siegfried B. Christensen, IV , Jinhwa Lee , Daniel J. Mercer
Inventor： Jia-Ning Xiang , Siegfried B. Christensen, IV , Jinhwa Lee , Daniel J. Mercer
IPC: A61K31/535 , C07C271/00
CPC classification number: C07D295/192 , C07C243/32 , C07C243/38 , C07C281/02 , C07C281/06 , C07C2601/08 , C07C2601/14 , C07D295/13 , C07D295/215
Abstract: Novel PDF inhibitors and novel methods for their use are provided.
-
-
-
-
-
-
-
-
-
Search Results
126
records
(took 0.06 seconds)
